BioSpace News Archive

New Mexico Cancer Center and Deep Lens announced a strategic partnership that will integrate artificial intelligence -based clinical trial screening and enrollment solution, VIPER™, into the NMCC network.

For the second time in a row, Vetter, a global leading contract development and manufacturing organization, has won the Axia Best Managed Companies Award.

A new study demonstrates the ability of a novel liquid formulation of levothyroxine, TirosintSol® developed and commercialized in the United States by IBSA Pharma Inc., to be administered as early as 15 minutes before breakfast without interfering with absorption and systemic availability

Concurrently with conversion of debt, the Company closed a non-brokered private placement financing at a price of $0.20 per Share, by issuing 200,000 Shares for total gross proceeds of $40,000.

“After only a few weeks as president of Green Star Products, it became evident that the Company would soon be entering a world market without a professional team to navigate the intricacies associated with international markets and trade.”

Each day, as many as 300,000 Canadians living with type 1 diabetes will make up to 300 decisions about their care.

Strategic collaboration ensures veterinarians have rapid, easy access to LAVERDIA™-CA1 (verdinexor), the first oral tablet conditionally approved by the U.S. Food and Drug Administration (FDA) to treat lymphoma in dogs

- Castor is supporting more than 250 COVID-19 studies in 40 countries across 1,750 hospitals - Offers an expanded suite of tools and resources for clinical researchers in the fight against COVID-19 and other pandemic outbreaks

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”) announced today it has completed the acquisition of PRO-DIP, LLC, a U.S.-based company that has developed an innovative, patent-pending oral pouch delivery system technology which allows for broad market applications related to nutritionally focused products and medicinal based formulations

Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced that Mr. Ian Huen, Founder, Chief Executive Officer and Executive Director of the Company, through his wholly owned investment company Jurchen Investments Limited,